Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
Lilly's retatrutide phase 3 results: 28.3% body weight loss on highest dose May 2026 Eli Lilly's phase 3 results for retatrutide show striking efficacy in obesity treatment: 28.3% body weight loss on the highest dose over 80 weeks approximately 70 lbs on average 45% of participants lost 30% or more of their body weight 65% on the top dose were no longer clinically obese Even the lowest 4mg dose delivered 19% weight loss with fewer dropouts than placebo Retatrutide is a triple-agonist targeting GIP, GLP-1, and glucagon receptors versus one receptor for semaglutide and two for tirzepatide (Mounjaro/Zepbound)
Common side effects include gastrointestinal symptoms for both supplements
This could potentially benefit memory, focus, and overall mental clarity, though more research is needed to fully understand these effects
The GLP-1 that does reach the pancreas calls for the release of more insulin when food is being broken down and absorbed
When used consistently, it improves skin clarity and tone
US$ 21.80
:max_bytes(150000):strip_icc()/anxiety-treatment-and-lexapro-dosage-and-side-effects-3024961-01-5c93d4c546e0fb00014427d3.png)
US$ 28.50
US$ 24.95
US$ 28.86
US$ 22.41
